Accelerate Registration of Medical Products

Limited access to safe and efficacious quality medical products for people in low and middle-income countries has many reasons. One increasingly recognised factor are lengthy and unreliable product assessment and approval procedures for applicants. Through the Swiss Agency for Therapeutic Products and SDC, Switzerland has become one of the key partners in supporting African medicines regulatory systems become more efficient. Both will expand their engagement in Africa and globally.

Pays/région Thème Période Budget
Monde entier
Renforcement des systèmes de santé
01.01.2019 - 31.12.2021
CHF  3’542’550
Contexte Access to safe and efficacious quality medical products is a complex issue. It spans from research and development of innovative products to sustainable financing of these products and the appropriate use of the products by the patient in need. An increasingly recognised factor delaying access are lengthy assessment and approval procedures that may last up to 7 years in some low and middle income countries. This “drug-lag” causes unnecessary ill-health and death. One way of shortening and making the evaluation and approval process more transparent are product assessments jointly conducted by several national medicine agencies of one region and supported by the World Health Organisation and technical partners such as the Swiss Agency for Therapeutic Products.
Objectifs Improve access to efficacious and safe quality medical products for people in low and middle-income countries, especially in sub-Saharan Africa, through medicines regulatory systems strengthening at the global, regional and country level.
Groupes cibles Primary beneficiaries are people in African and other low and middle-income countries who are in need of medical products for which marketing authorisation at the level of Swissmedic, WHO pre-qualification programme and national medicine regulatory authorities in Africa is sought. Secondary beneficiaries are national medicine regulatory authorities and regional economic communities in Africa that benefit from technical regulatory systems strengthening support provided by WHO and Swissmedic. Pharmaceutical companies that seek marketing authorisation for their medical product candidates are also secondary beneficiaries.
Effets à moyen terme

Outcome 1: Quality and speed of evaluation and registration procedures of jointly assessed medical products in low and middle-income countries has increased at regional and country level

Outcome 2: Number of jointly assessed medical products that are also registered at national level has increased.


Principaux résultats attendus:  

Output 1: Harmonized technical guidelines, standards and procedures are established, regularly updated and implemented at regional and country level by 2020 (EAC, ECOWAS, IGAD, OCEAC).

Output 2: Medical product dossiers submitted through regional procedure are jointly assessed by NMRAs in a region according to harmonised guidelines and established standards and procedures.

Output 3: Manufacturing site inspections of pharmaceutical companies selling their products in the respective regional economic communities are jointly conducted by NMRAs in a region according to harmonised guidelines and established standards and procedures.

Output 4: Capacities of regulatory staff from African NMRAs and regional networks strengthened through acquired appropriate knowledge and skills

Output: 5: Technical support provided by different partners to national medicines regulatory authorities or regional regulatory networks is efficiently coordinated by WHO through the Coalition of Interested Partners (CIP).

Output 6: Swissmedic marketing authorisation and scientific advice procedure for medical products against diseases disproportionately affecting people in low and middle-income countries is used by relevant applicants (e.g. Product Development Partnerships; pharmaceutical companies).

Principaux résultats antérieurs:  

  • East African Community (EAC):
  • 62 applications received for EAC joint assessment and registration, with 15 products recommended for registration at national level

  • 14 joint manufacturing site inspections with 11 certificates issued

  • Reductions in approval timelines from an average of 24 months at baseline, to 12 months or shorter

  • Swissmedic Market Authorisation Procedure for Global Health Products: 2 products under evaluation (for tuberculosis and for post-partum haemorrhage)

Direction/office fédéral responsable DDC
Crédit Coopération au développement
Partenaire de projet Partenaire contractuel
Organisme des Nations Unies (ONU)
  • Organisation mondiale de la santé

Autres partenaires
Swiss Agency for Therapeutic Products (Swissmedic), Bill and Melinda Gates Foundation, Agency for New Partnership for Africa’s Development, African Regional Economic Communities
Coordination avec d'autres projets et acteurs Drugs for Neglected Diseases Initiative, Medicines for Malaria Venture, Foundation for New Innovative Diagnostics, Medicines Patent Pool
Budget Phase en cours Budget de la Suisse CHF    3’542’550 Budget suisse déjà attribué CHF    3’247’338
Phases du projet Phase 2 01.01.2019 - 31.12.2021   (Phase en cours) Phase 1 01.12.2015 - 31.12.2018   (Completed)